Jenneke Keizer-Garritsen

Jenneke Keizer-Garritsen

Auto-generated profile, based on publicly available information

Jenneke Keizer-Garritsen

Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in EBioMedicine
Verified
Journal Article
Open access
EWEsther Willems
Esther Willems
WAWynand Alkema
Wynand Alkema
JKJenneke Keizer-Garritsen
Jenneke Keizer-Garritsen
ASAnouk Suppers
Anouk Suppers
MFMichiel van der Flier
Michiel van der Flier
MJMarien I. de Jonge
Marien I. de Jonge
The complement system is a central component of the innate immune system. Constitutive biosynthesis of complement proteins is essential for homeostasis. Dysregulation as a consequence of genetic or environmental cues can lead to inflammatory syndromes or increased susceptibility to infection. However, very little is known about steady state levels in children or its kinetics during infection. With a newly developed multiplex mass spectrometry-based method we analyzed the levels of 32 complement proteins in healthy individuals and in a group of pediatric patients infected with bacterial or viral pathogens. In plasma from young infants we found reduced levels of C4BP, ficolin-3, factor B, classical pathway components C1QA, C1QB, C1QC, C1R, and terminal pathway components C5, C8, C9, as compared to healthy adults; whereas the majority of complement regulating (inhibitory) proteins reach adult levels at very young age. Both viral and bacterial infections in children generally lead to a slight overall increase in complement levels, with some exceptions. The kinetics of complement levels during invasive bacterial infections only showed minor changes, except for a significant increase and decrease of CRP and clusterin, respectively. The combination of lower levels of activating and higher levels of regulating complement proteins, would potentially raise the threshold of activation, which might lead to suppressed complement activation in the first phase of life. There is hardly any measurable complement consumption during bacterial or viral infection. Altogether, expression of the complement proteins appears surprisingly stable, which suggests that the system is continuously replenished. FUND: European Union's Horizon 2020, project PERFORM, grant agreement No. 668303.

1 January 2003 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
JKJenneke J. Keizer-Garritsen
Jenneke J. Keizer-Garritsen
CBConnie Brouwer
Connie Brouwer
LLLambert H.J. Lambooy
Lambert H.J. Lambooy
PRPatricia Ter Riet
Patricia Ter Riet
JBJos P.M. Bökkerink
Jos P.M. Bökkerink
RARonney A. De Abreu
Ronney A. De Abreu
Background: Monitoring 6-thiopurine S-methyltransferase (TPMT; EC 2.1.1.67) activity is especially important when patients are treated with 6-thiopurine drugs, since severe bone marrow toxicity may be induced if patients have deficient TPMT activity. Methods: We have developed a method based on high-performance liquid chromatography (HPLC) for the measurement of TPMT activity in various cell types: erythrocytes (RBC), human peripheral blood mononuclear cells (pMNC) and human malignant lymphoblasts (Molt-F4). The enzymatic activity is measured by the amount of 6-methylmercaptopurine formed, using 6-mercaptopurine (6MP) as substrate and S-adenosylmethionine as co-substrate. Results: The K m values calculated for 6MP were 0·54 (RBC), 0·85 (pMNC) and 0·65 (Molt-F4 cells) mmol/L. The K m values for S-adenosylmethionine were 11·9 (RBC), 16·4 (pMNC) and 6·65 (Molt-F4 cells) µmol/L. The assay variation was 8·2-17%. TPMT activity was determined in a control group of 103 children and young adults (44 female, 59 male). The values observed were (mean ± standard deviation): female children and young adults, 15·1 ± 4·8 pmol/10 7 cells per h ( n = 44); male children and young adults, 15·8 ± 6·4 pmol/10 7 cells per h ( n = 59). No gender or age differences were found. Conclusion: The HPLC-based method enables the rapid screening of TPMT activities in large groups of patients treated with 6-thiopurines.

25 November 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
IAIlhan Erkin Acar
Ilhan Erkin Acar
EWEsther Willems
Esther Willems
EKEveline Kersten
Eveline Kersten
JKJenneke Keizer-Garritsen
Jenneke Keizer-Garritsen
EKElse Kragt
Else Kragt
AHAnneke I. den Hollander
Anneke I. den Hollander
Age-related macular degeneration (AMD) is a major cause of vision loss among the elderly in the Western world. The complement system has been identified as one of the main AMD disease pathways. We performed a comprehensive expression analysis of 32 complement proteins in plasma samples of 255 AMD patients and 221 control individuals using mass spectrometry-based semi-quantitative multiplex profiling. We detected significant associations of complement protein levels with age, sex and body-mass index (BMI), and potential associations of C-reactive protein, factor H related-2 (FHR-2) and collectin-11 with AMD. In addition, we confirmed previously described associations and identified new associations of AMD variants with complement levels. New associations include increased C4 levels for rs181705462 at the C2/CFB locus, decreased vitronectin (VTN) levels for rs11080055 at the TMEM97/VTN locus and decreased factor I levels for rs10033900 at the CFI locus. Finally, we detected significant associations between AMD-associated metabolites and complement proteins in plasma. The most significant complement-metabolite associations included increased high density lipoprotein (HDL) subparticle levels with decreased C3, factor H (FH) and VTN levels. The results of our study indicate that demographic factors, genetic variants and circulating metabolites are associated with complement protein components. We suggest that these factors should be considered to design personalized treatment approaches and to increase the success of clinical trials targeting the complement system.